【toyota sequoia with captains chairs】What Should You Know About The Future Of AstraZeneca PLC’s (LON:AZN)?
After AstraZeneca PLC’s (
LON:AZN
) earnings announcement in September 2018,toyota sequoia with captains chairs analysts seem cautiously optimistic, with profits predicted to increase by 10.0% next year against the past 5-year average growth rate of 7.6%. With trailing-twelve-month net income at current levels of US$3.0b, we should see this rise to US$3.3b in 2020. I will provide a brief commentary around the figures and analyst expectations in the near term. For those interested in more of an analysis of the company, you can
research its fundamentals here
.
View our latest analysis for AstraZeneca
Can we expect AstraZeneca to keep growing?
Longer term expectations from the 25 analysts covering AZN’s stock is one of positive sentiment. Given that it becomes hard to forecast far into the future, broker analysts tend to project ahead roughly three years. To understand the overall trajectory of AZN’s earnings growth over these next fews years, I’ve fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope.
LSE:AZN Future Profit January 1st 19
From the current net income level of US$3.0b and the final forecast of US$6.5b by 2022, the annual rate of growth for AZN’s earnings is 27%. EPS reaches $3.99 in the final year of forecast compared to the current $2.37 EPS today. In 2022, AZN’s profit margin will have expanded from 13% to 22%.
Next Steps:
Future outlook is only one aspect when you’re building an investment case for a stock. For AstraZeneca, there are three relevant aspects you should look at:
Financial Health
: Does it have a healthy balance sheet? Take a look at our
free balance sheet analysis with six simple checks
on key factors like leverage and risk.
Valuation
: What is AstraZeneca worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The
intrinsic value infographic in our free research report
helps visualize whether AstraZeneca is currently mispriced by the market.
Other High-Growth Alternatives
: Are there other high-growth stocks you could be holding instead of AstraZeneca? Explore
our interactive list of stocks with large growth potential
to get an idea of what else is out there you may be missing!
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at
.
View comments
(责任编辑:Leisure)
- Westland Insurance Acquires Diamond Insurance Agencies in Alberta
- Can Hang Seng Recover From Its 6-Month Long Decline?
- Why CF Industries Holdings, Inc. (NYSE:CF) Is A Dividend Rockstar
- US Market Indexes Close Higher on First Trading Day of 2019
- Is MYR Group (MYRG) a Great Value Stock Right Now?
- Amazon Will Take the Next Step of Its Whole Foods Strategy in 2019
- Dow futures higher | Jobs report set | Amazon drops 4% after earnings call
- W.R. Berkley Corp. Appoints Philip Welt as GC, Executive VP
- Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties
- Normani cancels BET Awards performance because of rehearsal injury
- You Can Own This Lotus Cortina Raced by Some of the World's Greatest Drivers
- Riverdale recap: A fog forces some serious conversations
- Crude Oil Price Update – Close Over $35.79 Forms Potentially Bullish Closing Price Reversal Bottom
- China's manufacturing sector shrinks more than expected in January - Caixin PMI
- Can You Imagine How Eagle Nice (International) Holdings's (HKG:2368) Shareholders Feel About The 96% Share Price Increase?
- Disney Infinity Expansion Includes More Marvel and Star Wars
- Get Disruptive in 2019 With These 10 ETFs
- BRIEF-Wuxi New Hongtai Electrical Technology Scraps Asset Restructuring
- LeadsRx and WideOrbit Partnership Gives Advertisers Access to Advertising Campaign Data to Maximize ROAS
- BRIEF-Bermaz Auto Bhd Says Lee Kok Chuan Redesignated To CEO From Executive Director